Scott Ripley, PhD, is the general manager, nucleic acid therapeutics (NAT), at Cytiva, which is focused on supporting the clinical manufacture of mRNA-LNP and other nucleic acid–based therapies. He is deeply involved in both the strategic and tactical aspects of evolving and driving forward products and services that support advanced therapeutic manufacturing. With over two decades of experience in life sciences, Scott’s success has been built upon his exceptional customer focus.